Polycyclic dianthraquinones as anti-cancer and anti-angiogenic agents
CA 2396704 A1 · Owner: Yeda Research And Development Co. Ltd. · Inventors: Mazur, Yehuda; Lavie, Gad
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Hypericin, helianthrone and derivatives thereof of general formula (I) wherein the dotted line between positions 11 and 12 represents an optional C11-C12 bond; R is selected from the group consisting of hydroxy C1-C10 alkoxy, NH-C1-, C10 alkyl, and NH-hydroxy(C1-C10)alkyl but R is H at positions 8 and 15 when there is no C11-C12 bond; R' is selected from the group consisting of hydroxy and C1-C10 alkoxy; and R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen, hydroxy chloro, bromo, C1-C10 alkyl, C1-C10 alkoxy and C1-C10 alkoxycarbonyl, are useful as inhibitors of angiogenesis and can be used to prevent formation of metastases and restenosis and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 31, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 31, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 31, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.